Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 8/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573025 | 1.00 | CSNK2A1 (0.55) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL849501 | 0.92 | CSNK2A1 (0.60) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL23932310 | 0.82 | CSNK2A1 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL827047 | 0.82 | GPR84 (0.54) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL916811 | 0.79 | GPR84 (0.47) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL916587 | 0.75 | GPR84 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL1076943 | 0.75 | CSNK2A1 (0.85) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL25594837 | 0.75 | CSNK2A1 (0.55) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL29507011 | 0.75 | GPR84 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL2960506 | 0.75 | CSNK2A1 (0.55) | CSNK2A1AHRCYP2A6NR4A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| CN-119899150-A | Synthetic method and application of 3-trifluoromethyl quinoline compound | 遵义医科大学 | 2025-04-29 | — | — | CN | disclosed |
| EP-4531858-A1 | NOVEL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119300833-A | Novel compounds | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12172995-B2 | Substituted indole and indazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | disclosed |
| CN-119019362-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023232917-A1 | NOVEL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| EP-2125749-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008100456-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100456-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1742912-A1 | NOVEL ANDROGENS | N.V. Organon (NL) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | CSNK2A1 334/4885AHR 354/4885CYP2A6 154/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | CSNK2A1 2005/4885AHR 1827/4885CYP2A6 682/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | CSNK2A1 778/4885AHR 2604/4885CYP2A6 716/4885 |
| US-12172995-B2 | Substituted indole and indazole compounds | TLR1, TLR7, IDO1 | CSNK2A1 518/4885AHR 95/4885CYP2A6 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.